Mandate

Vinge advises Industrifonden in connection with investment in Footway

January 26, 2012

Vinge has advised Industrifonden in connection with its investment in Footway, an e-trading company which sells shoes online. The investment was part of a new issue of shares under which Footway raised SEK 28 million from Industrifonden, eEquity and the company’s founders.  One of the key figures in Footway is Daniel Mühlbach, who played a prominent role in the success of Lensway. The money will be used for Footway’s expansion in the Nordic region.

Industrifonden invests in small and medium sized companies which exhibit the potential for international growth. The fund has assets of SEK 3.8 billion and investments in 89 companies within the technology, cleantech, life science and industrial sectors. 

Vinge’s team consisted of partner Johan Larsson and associate Martin Hall.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024